Paradoxical Efficacy With Rare Adverse Events: Sequential ALK Inhibitor Therapy in Lung Adenocarcinoma

Area of Science:

• Oncology
• Pharmacology
• Pulmonology

Background:

• Anaplastic lymphoma kinase (ALK) inhibitors have transformed outcomes for ALK-positive non-small cell lung cancer (NSCLC).
• Rare and organ-specific toxicities associated with these tyrosine kinase inhibitors (TKIs) are often underreported, complicating clinical management and rechallenge strategies.
• Effective management of TKI-induced adverse events requires a comprehensive understanding of potential toxicities.

Purpose of the Study:

• To report a unique case of sequential organ toxicities during Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) therapy and rechallenge in a patient with advanced non-small cell lung cancer (NSCLC).
• To highlight the potential for drug-induced interstitial pneumonitis and severe cutaneous adverse events in the context of ALK TKI treatment.
• To underscore the need for increased clinical vigilance and the development of predictive biomarkers for managing TKI-associated toxicities.

Main Methods:

• Case report of a patient with advanced ALK-positive NSCLC treated with ensartinib and subsequently lorlatinib.
• Detailed clinical observation of treatment response, adverse events including interstitial pneumonitis and cutaneous toxicity, and management strategies.
• Review of literature regarding rare toxicities of ALK inhibitors.

Main Results:

• The patient achieved rapid tumor regression with ensartinib, but developed mild bilateral interstitial pneumonitis, which resolved upon drug cessation.
• Following disease progression, rechallenge with lorlatinib resulted in severe cutaneous toxicity, responsive to corticosteroid treatment.
• This case represents the first report of ensartinib-induced interstitial pneumonitis and demonstrates a dissociation between tumor response and pulmonary toxicity, alongside sequential multiorgan toxicities.

Conclusions:

• Heightened vigilance and multidisciplinary management are crucial for anticipating and managing rare TKI-associated toxicities in ALK-positive NSCLC.
• The development of predictive biomarkers is essential for personalizing toxicity monitoring and guiding safe rechallenge strategies with ALK TKIs.
• Further prospective studies are needed to optimize treatment protocols and improve patient outcomes in ALK-positive NSCLC.